Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

THOUSAND OAKS, Calif., June 5, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Goldman Sachs 46 th Annual Global Healthcare Conference at 9:20 ...

Amgen AMGN announced encouraging new data from its interim analysis of the global late-stage study evaluating Imdelltra ...

Amgen (NasdaqGS:AMGN) recently announced interim results from its Phase 3 DeLLphi-304 trial for IMDELLTRA, showing ...

With 14 drugs posting double-digit sales growth in the most recent quarter, a promising obesity drug in late-stage trials, ...

Amgen's Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease ...

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer ...

Federal jurors in Delaware found that Amgen violated antitrust laws by bundling its cholesterol treatment with substantial ...

Nplate improved platelet response and reduced therapy modification for patients with chemotherapy-induced thrombocytopaenia.

Amgen's Nplate, which treats low blood platelet counts caused by an autoimmune condition, was highly effective at preventing ...

Amgen said interim results from a Phase 3 trial showed Imdelltra reduced the risk of death and other benefits for patients with small cell lung cancer.